Questions on Neurim scope remain post-SPC ruling, say lawyers

The Court of Justice of the European Union’s (CJEU) recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates (SPC) last week has left some big questions unanswered.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Neurim prevails against Mylan in suit over insomnia drug

8 December 2020 Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.

Big Pharma

CJEU puts further brakes on SPCs

22 March 2019 The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Questions on Neurim scope remain post-SPC ruling, say lawyers

More on this story

Editor's picks

Editor's picks

More features